checkAd

     132  0 Kommentare NANOBIOTIX Announces First Quarter 2020 Revenues

    Regulatory News:

    NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenues for the first quarter of 2020.

    In K€ (unaudited)

    Q1 2020

    Q1 2019

    Revenues

    24

    5

     

     

     

    Of which licenses

    -

    -

    Of which services

    24

    5

    Activity and results

    Nanobiotix’ revenue for the first quarter 2020 amounted to €24k.

    Most of the revenues generated by the Company during this period result from the crossed charged to our partner, PharmaEngine, of shared external contract research organization costs pursuant to our license and collaboration agreement.

    The amount of cash and cash equivalent as of March 31st, 2020 amounted to €28m.

    In January 2020, the Company announced its Head and Neck phase III registration trial (Study 312) and global development strategy for 2020.

    Study 312 is a phase III, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy. The design of study 312 is currently under review by the U.S. Food and Drug Administration (FDA). In February 2020, NBTXR3 received Fast Track designation by the US FDA in that indication. Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

    Once approved, the trial will launch as soon as the requisite financing is secured. The trial should recruit around 500 patients with the initial readout based on event-driven progression-free survival (PFS), and the final readout on PFS and overall survival (OS). A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS.

    Seite 1 von 3


    Business Wire (engl.)
    0 Follower
    Autor folgen

    NANOBIOTIX Announces First Quarter 2020 Revenues Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenues for the first …